BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15999992)

  • 1. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.
    Kuo GH; Deangelis A; Emanuel S; Wang A; Zhang Y; Connolly PJ; Chen X; Gruninger RH; Rugg C; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
    J Med Chem; 2005 Jul; 48(14):4535-46. PubMed ID: 15999992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
    J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
    Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
    Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.
    VanderWel SN; Harvey PJ; McNamara DJ; Repine JT; Keller PR; Quin J; Booth RJ; Elliott WL; Dobrusin EM; Fry DW; Toogood PL
    J Med Chem; 2005 Apr; 48(7):2371-87. PubMed ID: 15801830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
    Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK
    J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
    Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
    J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.
    Tsou HR; Liu X; Birnberg G; Kaplan J; Otteng M; Tran T; Kutterer K; Tang Z; Suayan R; Zask A; Ravi M; Bretz A; Grillo M; McGinnis JP; Rabindran SK; Ayral-Kaloustian S; Mansour TS
    J Med Chem; 2009 Apr; 52(8):2289-310. PubMed ID: 19317452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.
    Kassis P; Brzeszcz J; Bénéteau V; Lozach O; Meijer L; Le Guével R; Guillouzo C; Lewiński K; Bourg S; Colliandre L; Routier S; Mérour JY
    Eur J Med Chem; 2011 Nov; 46(11):5416-34. PubMed ID: 21944287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
    Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
    Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor.
    Huang S; Lin R; Yu Y; Lu Y; Connolly PJ; Chiu G; Li S; Emanuel SL; Middleton SA
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1243-5. PubMed ID: 17234412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
    Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.
    Jacquemard U; Dias N; Lansiaux A; Bailly C; Logé C; Robert JM; Lozach O; Meijer L; Mérour JY; Routier S
    Bioorg Med Chem; 2008 May; 16(9):4932-53. PubMed ID: 18439832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
    Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
    J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.